Impedimed Limited · ASX:IPD
Impedimed — Q3 FY24 Earnings Presentation
24 slides from Impedimed's earnings presentation, Apr 30, 2024
Slide 1: ImpediMed ASX announcement: Investor Presentation
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 30 April 2024 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentatio
Slide 2: Investor Presentation for the Quarter Ended 31 March 2024
For personal use only Investor Presentation For the Quarter Ended 31 March 2024 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 1 ©2024 ImpediMed Limited.
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: FY24 Q3 Highlights
FY24 Q3 Highlights • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Survivorship V.1.2024 published For personal use only • BIS added to National Cancer Institute webpage. • ImpediMed associated authors presented further data from the PREVENT study on breast cancer-related lym
Slide 5: New Executive Leadership Team
New Executive Leadership Team For personal use only Parmjot Bains, MD McGregor Grant Steven Chen, MD Tim Benkovic Dennis Schlaht Andrew Grant Julie Kuhlken Managing Director / CEO Chief Financial & Chief Medical Officer SVP, Sales & Customer SVP, R&D and VP, Product Development Senior Director, Oper
Slide 6: Foundation in Place for Success in Lymphoedema; Focus on Execution
Foundation in Place for Success in Lymphoedema; Focus on Execution Unique Technology BIS | SOZO | L-DEX For personal use only Strong Clinical Evidence PREVENT Trial Guidelines Supporting National Comprehensive Cancer Network® Standard of Care (NCCN®) and multiple other guidelines Reimbursement 140 m
Slide 7: CEO Plan on a Page
CEO Plan on a Page Vision Revolutionize patient care through clinically validated fluid and body mass composition BIS digital solutions For personal use only Goals Goal 1: Goal 2: Goal 3: Goal 4: Goal 5: Ensure every new US Deliver world-class Expand reach for all Reach break even Develop innovative
Slide 8: Q3 Marketing Highlights
Q3 Marketing Highlights Lymphedema Awareness Month and Q3 activities to amplify awareness for Breast Cancer-Related Lymphedema (BCRL) education and management: For personal use only Thought Leadership Articles/Blogs/Podcasts: • MedCity News “Redefining Survivorship: Proactive Strategies for Preventi
Slide 9: Recent News
Recent News NCCN Guidelines for Survivorship V.1.2024 Published BIS Added to NCI Webpage NCCN Guidelines for Survivorship, V.1.2024 For personal use only SLYMPH-2: PRINCIPLES OF LYMPHEDEMA Early detection/diagnosis and early referral are key for optimal lymphedema management because stages 0 and 1 a
Slide 10: ASBrS Recap
ASBrS Recap A Huge Success For personal use only • Multiple Leads and KOL meetings • Positive Pre-Conference Presence: • Lymphatic Surgery Course (CPS Team with SOZO Demos & direct mention of SOZO/BIS) • APP Course (Dr Chen ImpediMed Sales Team at ASBrS Booth presented with high level of engagement)
Slide 11: ASBS Poster Presentation Highlights
ASBS Poster Presentation Highlights Results Discussion/Conclusions • For personal use only Median follow-up time was 35.6 months • This study provides additional evidence supporting the • 209/918 (22.8%) patients developed sBCRL need for continued lymphedema follow-up and the use • 52.6% of those wi
Slide 12: Q3 Key Publications – Real World Evidence Generation
Q3 Key Publications – Real World Evidence Generation For personal use only ImpediMed presented further results from its randomized breast cancer-related lymphedema study at a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024 “"T
Slide 13: Financials and Key Metrics
For personal use only Financials and Key Metrics Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 12
Slide 14: Revenue Metrics: Continuing Growth in ARR and Low Churn
Revenue Metrics: Continuing Growth in ARR and Low Churn For personal use only Revenue Core Business TCV1 Core Business ARR2 Churn3 3% Churn Rate based on SOZO Systems globally 1.Total Contracted Value (TCV) includes any consideration for the sale of SOZO Systems as well as the total Software-as-a Se
Slide 15: Cash
Cash For personal use only Summarized cash flow FY24 • Q3 FY24 net cash outflows from operating In thousands AUD Q1 Q2 Q3 YTD activities of A$6.3 million: Cash at beginning of period 45,710 42,398 36,905 45,710 • Net of cash receipts from customers of A$2.6 million. Net cash flow from operating acti
Slide 16: Growing Installed Base and Increased Utilisation Driving Increased Patient Testing
Growing Installed Base and Increased Utilisation Base Driving Increased Patient Testing Global Installed Base SOZO Patient Tests For personal use only 37% 5-year CAGR1 U.S. Rest of World 1.Compound Annual Growth Rate Charts are not to scale and therefore are not comparable 15 Proprietary, do not rep
Slide 17: Strong Fundamentals
For personal use only Strong Fundamentals Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 16
Slide 18: Supported by Level Clinical Evidence taken into Guidelines
Supported by Level 1 Clinical Evidence taken into Guidelines Significantly lower progression to chronic lymphoedema with early detection using L-Dex® and For personal use only intervention versus using Standard of Care (tape measure) • PREVENT Trial: multi-center, international RCT • n = 1,200 • 10
Slide 19: Guidelines Support Subclinical Detection, Intervention and BIS
Guidelines Support Subclinical Detection, Intervention and BIS National Comprehensive Cancer Network® (NCCN®) American Society of Breast Surgeons For patients and survivors at risk for lymphedema: For personal use only For breast cancer patients: NCCN • Recommends regular lymphedema screening for ly
Slide 20: Market Opportunity
Market Opportunity Annual cancer diagnoses in the US by cancer type1 Economics of market driven by diagnoses, tests per patient and reimbursement rates For personal use only Breast 290,560 Breast Non-Breast All at-risk Cancer Cancer Cancers5 Colorectal 160,470 15% Annual diagnoses1 290k 820k 1.1M Pa
Slide 21: BIS and SOZO
For personal use only BIS and SOZO Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 20
Slide 22: ImpediMed's Technology
ImpediMed’s Technology Using Bioimpedance Spectroscopy (BIS), SOZO non-invasively measures, monitors and manages fluid status and For personal use only tissue composition Subjective and Time Consuming BIS is Objective and Fast Imaging Low Frequency Current passes around cells Fluid Implantables 256
Slide 23: SOZO Digital Health Platform: One device, multiple applications
SOZO® Digital Health Platform: One device, multiple applications A single SOZO measurement provides: For personal use only • L-Dex® lymphoedema analysis • Fat-free mass • HF-Dex heart failure analysis • Fat mass • Hy-Dex® hydration analysis • Skeletal muscle mass • Total body water • Protein and min
Slide 24: L-Dex Analysis for Lymphoedema
L-Dex® Analysis for Lymphoedema Designed for Lymphoedema For personal use only The L-Dex® score is designed to detect lymphoedema- related fluid changes in the arms. Accurate Detection L-Dex ® score is clinically validated to help detect lymphoedema at its earliest, subclinical stage. Demonstrated O